William Blair Weighs in on Agenus' Q4 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN - Free Report) - Equities researchers at William Blair cut their Q4 2024 earnings per share (EPS) estimates for shares of Agenus in a research note issued to investors on Tuesday, November 12th. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings of ($2.85) per share for the quarter, down from their previous forecast of ($2.81). William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($10.26) per share. William Blair also issued estimates for Agenus' Q1 2025 earnings at ($2.90) EPS, Q2 2025 earnings at ($3.07) EPS, Q3 2025 earnings at ($3.22) EPS, Q4 2025 earnings at ($3.31) EPS, FY2025 earnings at ($12.51) EPS, FY2026 earnings at ($13.03) EPS and FY2027 earnings at ($12.97) EPS.

A number of other brokerages also recently issued reports on AGEN. HC Wainwright cut their price target on shares of Agenus from $8.00 to $7.00 and set a "neutral" rating for the company in a report on Tuesday. Jefferies Financial Group reissued a "hold" rating and set a $7.00 target price (up previously from $3.00) on shares of Agenus in a research note on Friday, July 19th. Baird R W lowered Agenus from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 19th. Robert W. Baird cut Agenus from an "outperform" rating to a "neutral" rating and lowered their price target for the stock from $35.00 to $8.00 in a report on Friday, July 19th. Finally, StockNews.com lowered shares of Agenus from a "hold" rating to a "sell" rating in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $10.00.

Agenus Trading Down 1.8 %

AGEN stock traded down $0.05 during trading on Friday, reaching $2.72. 1,071,943 shares of the stock were exchanged, compared to its average volume of 649,029. The firm has a market capitalization of $63.81 million, a price-to-earnings ratio of -0.24 and a beta of 1.39. The business has a 50 day moving average price of $4.70 and a 200-day moving average price of $8.70. Agenus has a 1 year low of $2.58 and a 1 year high of $19.69.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC lifted its position in shares of Agenus by 295.3% during the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company's stock worth $152,000 after purchasing an additional 20,777 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Agenus in the third quarter valued at $55,000. State Street Corp boosted its holdings in Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company's stock valued at $2,563,000 after purchasing an additional 9,731 shares during the period. Point72 DIFC Ltd increased its holdings in Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 11,542 shares during the period. Finally, HighTower Advisors LLC raised its position in Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 7,530 shares in the last quarter. Hedge funds and other institutional investors own 61.46% of the company's stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.